1. Switzerland Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - General
Novartis AG

Novartis AG

NVS.TO
Novartis AGCA flagToronto Stock Exchange
28.24
CAD
+0.19
- -
51.69BMarket Cap
Novartis AG
NVS.TO
(Toronto Stock Exchange)

Recent

price

28.24

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
3.37
3.72
3.21
3.22
3.3
3.13
3.1
2.76
2.97
3.17
3.27
2.93
2.97
3.35
3.83
4.36
4.43
Revenue per Share
0.64
0.56
0.57
0.56
0.63
1.1
0.42
0.49
0.81
0.76
0.53
1.6
0.48
1.07
0.88
1.08
1
Basic EPS, GAAP
0.77
0.75
0.7
0.6
0.65
0.52
0.54
0.66
0.75
0.74
0.73
0.83
0.82
0.84
1.02
1.17
1.17
Free Cash Flow per Basic Share
0.29
0.34
0.37
0.37
0.42
0.41
0.41
0.41
0.45
0.43
0.46
0.49
0.51
0.52
0.56
0.6
0.71
Dividend per Share
27.6
27.36
28.56
30.64
29.5
32.46
31.52
32
34.01
24.49
25.08
30.27
28
22.83
22.3
24.18
21.86
Book Value per Share
-0.75
1.63
3.19
6.38
7.35
4.91
5.27
5.36
1.99
0.07
-4.52
1.74
-0.76
-1.74
-3.86
-4.64
-14.36
Tangible Book Value per Share
15,318
15,961
16,203
16,356
16,256
16,102
15,934
15,720
15,539
15,351
15,257
15,029
14,614
13,916
13,522
12,992
12,791
Basic Weighted Avg Shares
51,561
59,375
51,971
52,716
53,634
50,387
49,436
43,404
46,099
48,677
49,898
43,974
43,461
46,660
51,722
56,674
56,693
Sales/Revenue/Turnover
22.35
18.16
22.14
20.83
20.68
17.82
16.72
20.05
18.23
18.67
20.35
22.87
18.28
20.94
28.12
31.13
30.17
Operating Margin (%)
3,419
5,788
4,442
4,405
4,682
5,471
6,043
4,736
5,211
5,826
6,464
5,597
6,705
8,277
6,069
5,325
5,543
Depreciation Expense
9,794
8,940
9,270
9,175
10,210
17,783
6,712
7,703
12,611
11,732
8,072
24,021
6,955
14,850
11,941
13,984
12,757
Net Income, GAAP
14.81
14.05
15.18
13.86
12.59
13.6
14.31
17.61
9.19
20.06
18.29
6.62
15.72
6.04
12.47
14.59
17.88
Effective Tax Rate (%)
18.99
15.06
17.84
17.4
19.04
35.29
13.58
17.75
27.36
24.1
16.18
54.63
16
31.83
23.09
24.67
22.5
Profit Margin (%)
2,027
936
3,953
4,174
10,588
-863
2,722
4,805
5,956
1,240
-3,386
15,510
8,254
4,091
1,012
3,182
-4,397
Working Capital
14,360
13,855
13,781
11,242
13,799
16,327
17,897
23,224
22,470
22,056
27,978
24,523
21,782
20,034
22,934
29,592
39,152
LT Debt
69,769
65,940
69,263
74,472
70,844
77,122
74,891
74,227
78,692
55,551
56,666
67,822
59,423
46,750
44,126
46,549
41,946
Total Equity
11.43
9.94
10.76
10.14
10.26
7.96
7.02
6.98
7
7.25
8.97
9.42
6.96
11.05
16.64
18.61
16.45
Return on Invested Capital (%)
12.44
10.57
11.16
10.64
11.72
19.29
7.42
8.27
12.61
12.69
9.8
25.61
8.2
19.51
17.27
19.04
16.79
Return on Capital (%)
16.24
13.86
13.74
12.79
14.07
24.06
8.84
10.34
16.51
17.5
14.41
38.66
10.95
28.02
26.33
31.01
30.55
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
5,784
7,888
9,862
LT Borrowings
27,935
37,447
37,489
LT Finance Leases
1,657
1,663
1,663
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,908
1,908
1,901
Market Capitalization
36,169
39,301
40,507

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
30,460
26,607
27,351
Cash, Cash Equivalents & STI
11,533
6,977
7,690
Accounts Receivable, Net
8,937
9,386
9,636
Inventories
6,269
6,286
6,220
Total Current Liabilities
27,278
31,374
31,748
Payables & Accruals
9,517
6,129
6,570
ST Debt
5,784
7,888
9,862
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-3.93%
-2.83%
5.49%
Free Cash Flow
6.52%
6.98%
10.42%
Net Income, GAAP
21.56%
47.51%
17.11%
Sales/Revenue/Turnover
1.5%
2.95%
9.57%
Total Cash Common Dividend
1.72%
2.32%
2.54%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
12,120
12,872
13,172
13,558
51,722
2025
13,620
14,836
14,358
13,860
56,674
2026
13,524
14,951
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.2
0.24
0.24
0.21
0.88
2025
0.27
0.31
- -
0.19
1.08
2026
0.25
0.26
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.38
0.18
- -
- -
0.56
2025
0.4
0.19
- -
- -
0.6
2026
0.48
0.22
- -
- -
- -
Similar Companies
Merck & Co., Inc. (MRK.PA)
Roche Holding AG (RHHBY)
PT Kalbe Farma Tbk. (PTKFF)
Otsuka Holdings Co., Ltd. (OTSKY)
GlaxoSmithKline Pharmaceuticals Limited (GLAXO.BO)
GuangYuYuan Chinese Herbal Medicine Co., Ltd. (600771.SS)
Business
Novartis AG is a Switzerland-based innovative medicines company that researches, develops, manufactures and commercializes prescription therapies for serious diseases. Its principal products include immunology medicines such as Cosentyx for inflammatory diseases, Xolair for allergic conditions and Rhapsido for chronic spontaneous urticaria; cardiovascular, renal and metabolic medicines including Entresto for heart failure, Leqvio for cholesterol reduction, Fabhalta for complement-mediated and renal diseases, and Vanrafia for immunoglobulin A nephropathy; oncology therapies including Kisqali for breast cancer, Pluvicto and Lutathera radioligand therapies, Scemblix for chronic myeloid leukemia, Tafinlar and Mekinist for melanoma and other cancers, Jakavi for myeloproliferative neoplasms, and Ilaris for inflammatory conditions; neuroscience medicines including Kesimpta for multiple sclerosis, Aimovig for migraine, Zolgensma and Itvisma gene therapies for spinal muscular atrophy; and ophthalmology and established medicines. The company operates as a pure-play innovative-medicines business across four core therapeutic areas—cardiovascular-renal-metabolic, immunology, neuroscience and oncology—and prioritizes chemistry, biotherapeutics, gene and cell therapy, radioligand therapy and xRNA platforms. It serves patients, healthcare providers, hospitals, payers and public-health systems globally, with priority commercial geographies comprising the United States, China, Germany and Japan. Novartis was founded in 1996 and is headquartered in Basel, Switzerland. In recent developments, Novartis completed the acquisition of Avidity Biosciences in February 2026, making Avidity an indirect wholly owned subsidiary and adding a muscle-directed antibody oligonucleotide conjugate platform and late-stage neuromuscular programs; completed the acquisitions of Pikavation Therapeutics and Excellergy, including the Exl-111 allergic-disease asset; and entered into an agreement to acquire Myricx Bio to expand its oncology pipeline with B7-H3- and HER2-targeted antibody-drug conjugate candidates and an associated payload platform. The company also recently advanced launches and regulatory activity for Rhapsido, Itvisma and Fabhalta, while submitting a US biologics license application for del-zota, an investigational exon-skipping therapy for Duchenne muscular dystrophy.